Pilot Study of Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
The purpose of this study is to see if adding local treatments to erlotinib therapy can benefit patients who are newly diagnosed with EGFR-mutant lung adenocarcinoma present in no more than five sites of the body. Erlotinib is an anticancer drug that inhibits the EGFR protein. It is used in patients whose cancers contain mutations in the EGFR gene.
Patients in this study will receive erlotinib for 12 weeks. Those whose cancer shrinks or does not grow will then receive local treatment (such as surgery, stereotactic radiosurgery, ablation, or conventional radiation therapy) to all sites of disease. Once the local treatment is completed, patients will continue to receive erlotinib as long as the cancer does not grow.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must be newly diagnosed with adenocarcinoma of the lung that is present in no more than five sites and contains an EGFR mutation.
- Patients may not have received prior therapy for this cancer, including any prior treatment with erlotinib.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Helena Yu at 646-888-4274.